CVS Health announced it will reinstate coverage for Eli Lilly’s weight loss drug Zepbound and include its newly approved obesity pill, Foundayo, in its standard drug plans. This change, effective October 1 for Zepbound and June 1 for Foundayo, levels the playing field between Lilly and Novo Nordisk, which previously had its drug Wegovy as the preferred obesity treatment on CVS plans. The decision is significant as it opens up more treatment options for patients and aligns with CVS’s goal of fostering competition in the GLP-1 medication market.
This move is expected to drive 10% to 15% additional savings across the weight management category, benefiting millions of Americans who will gain access to these medications. The inclusion of both Lilly’s and Novo’s GLP-1s in CVS Caremark’s standard formulary represents a strategic shift in the pharmacy benefit management landscape, potentially influencing stock performance for both companies as they navigate this competitive market.
Market professionals should note that while CVS’s decision enhances access to these drugs, coverage is not guaranteed for all patients, depending on plan sponsors’ choices. This development could impact market dynamics and pricing strategies in the obesity treatment sector.
Source: cnbc.com